Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Aldeyra Therapeutics, Inc. (ALDX)

« Back to company index

ALDX Chatter Timeline

Stock Ticker for ALDX

Most Active Tweeters for ALDX

UserTweets
@brendan_49 15
@Gambiste1 9
@fezziwig2019 8
@avidresearch 6
@stocknewstimes 4

Recent Tweets for ALDX

gcassidy718 @gcassidy718
$ALDX new high coming! 2.59 % change recently https://t.co/h8Yudy9fHu
December 7th 2019, 9:12am
ThisLincolnian @ThisLincolnian
Aldeyra Therapeutics $ALDX Shares Down 32.4% https://t.co/A2uLosnpM2
December 5th 2019, 12:12pm
WeekHerald @WeekHerald
Aldeyra Therapeutics $ALDX Trading Down 32.4% https://t.co/eMzRacyBrX
December 5th 2019, 12:12pm
Gambiste1 @Gambiste1
RT @PennyStocksMomo: PENNYSTOCKS ALERT: $ALDX - Aldeyra Therapeutics, Inc via ? https://t.co/KgNa6xObv5
December 5th 2019, 10:12am
PennyStocksMomo @PennyStocksMomo
PENNYSTOCKS ALERT: $ALDX - Aldeyra Therapeutics, Inc via ? https://t.co/KgNa6xObv5
December 5th 2019, 10:12am
ThisLincolnian @ThisLincolnian
Aldeyra Therapeutics $ALDX Shares Gap Down to $5.06 https://t.co/hAmQwBwm8m
December 4th 2019, 3:12pm
XBIcallTSLAput @XBIcallTSLAput
@brendan_49 What do you think of $aldx if allergic conjunctivitis were to hit but DES did not? Seems likely this wi… https://t.co/cv0bnzd7sY
December 4th 2019, 1:12pm
brendan_49 @brendan_49
@Opal_Chip $ALDX has a shocking pipeline for its valuation. Are near or medium term catalysts? This isn't like a da… https://t.co/w10Y9FrJK9
December 4th 2019, 1:12pm
Opal_Chip @Opal_Chip
@brendan_49 Hi - just getting up to speed on $ALDX (your 7-part thread was very helpful), and curious if you have a… https://t.co/llvjENeUz4
December 4th 2019, 1:12pm
avidresearch @avidresearch
@PRB51 @brendan_49 $ALDX Reproxalap being modestly different from $5.3B drug should be worth more than where it is now :)
December 4th 2019, 12:12pm
brendan_49 @brendan_49
So what? Why does this matter? Because if $ALDX announces in a month or two the FDA is cool w/ shortening the anal… https://t.co/m6ZsBRTxsl
December 4th 2019, 12:12pm
brendan_49 @brendan_49
Most interesting part of $ALDX call was last few minutes. Q: Can you change analysis timing and drug taper timing… https://t.co/2yRUT6Wygc
December 4th 2019, 12:12pm
brendan_49 @brendan_49
Brady seems to hint that $ALDX w/ shorten the analysis period and delay the tapering in part 2. But then Walker sa… https://t.co/AZ4tdWz4xH
December 4th 2019, 12:12pm
brendan_49 @brendan_49
The $OYST ph2 and ph3 DES trials were/are only 4 weeks long. So $ALDX could’ve opted for a shorter ph3 trial. https://t.co/RvcDq1FJgc
December 4th 2019, 11:12am
GroundTrader @GroundTrader
$ALDX Bounce back to $6?
December 4th 2019, 9:12am
BioTuesdays @BioTuesdays
Aldeyra reports positive topline results from Phase 3 dry eye disease trial $ALDX https://t.co/RWr0HNmrHQ
December 4th 2019, 9:12am
brendan_49 @brendan_49
Last take on $ALDX: basically, the ph2 DES implied ph3 part A could or should hit stat sig on both primary endpoint… https://t.co/DCTkgTOlEY
December 4th 2019, 9:12am
Just_Xu_It @Just_Xu_It
RT @avidresearch: $ALDX compared to Xiidra on eye dryness score in dry eye disease. Obviously, cross trial comparisons are hard. https://t.…
December 4th 2019, 8:12am
avidresearch @avidresearch
$ALDX compared to Xiidra on eye dryness score in dry eye disease. Obviously, cross trial comparisons are hard. https://t.co/4o4O5jmpUn
December 4th 2019, 8:12am
avidresearch @avidresearch
@brendan_49 $ALDX In my view drug clearly very effective and has a rapid onset of efficacy. Looking at ph2 and part… https://t.co/FEe5DEYZlA
December 4th 2019, 8:12am
brendan_49 @brendan_49
5/ In sum, DES/staining data weeks 8-12 worsened from ph2 to ph3, not obvious why. obvious $ALDX will hit both sign… https://t.co/mzkvXowlyC
December 4th 2019, 8:12am
brendan_49 @brendan_49
4/ It looks like $ALDX might ask regulators to focus on earlier time points, since their was a change in language o… https://t.co/nQOCSp9bLd
December 4th 2019, 8:12am
brendan_49 @brendan_49
3/ It doesn't look like there's a simple explanation for why $ALDX staining benefits compared to vehicle at weeks 8… https://t.co/jeyxdi7582
December 4th 2019, 8:12am
brendan_49 @brendan_49
2/ After achieving stat sig on staining at all time points in ph2, $ALDX, in ph3 part 1, wasn't even close at weeks… https://t.co/N4H1AGGCSI
December 4th 2019, 8:12am
brendan_49 @brendan_49
1/ In their ph2 DES trial, $ALDX was stat sig for staining at all time points. https://t.co/tFWJJejaPe https://t.co/rBLKR5N5at
December 4th 2019, 8:12am
dailypoliticaln @dailypoliticaln
Aldeyra Therapeutics $ALDX Shares Down 32.4% https://t.co/iI1tIKjZgN
December 3rd 2019, 10:12pm
ZolmaxNews @ZolmaxNews
Aldeyra Therapeutics $ALDX Shares Down 32.4% https://t.co/st74LmMMkY
December 3rd 2019, 10:12pm
BlueBioNow @BlueBioNow
$ALDX That's rough. . . -27.17 % change recently https://t.co/PJmOd2fRWo
December 3rd 2019, 8:12pm
MaisaCorp @MaisaCorp
$ALDX While reproxalap was statistically superior to the dosing group, it failed to reach statistical significance… https://t.co/iCyPLxJGia
December 3rd 2019, 6:12pm
MaisaCorp @MaisaCorp
$ALDX reported mixed results from the early stages of a trial to test topical ocular reproxalap in patients with dry eye disease.
December 3rd 2019, 6:12pm
avidresearch @avidresearch
@pick1998_2 $ALdX data much better than those prior examples.
December 3rd 2019, 4:12pm
spauldingIII @spauldingIII
@fezziwig2019 @pick1998_2 Fez weren’t you the worlds biggest $aldx bull on Twitter a few months ago? Why so negative?
December 3rd 2019, 4:12pm
fezziwig2019 @fezziwig2019
@pick1998_2 Considering P2b $ALDX data, I’d say Part 2 chance of success less than 50/50 - but not zero. https://t.co/apMiduglYo
December 3rd 2019, 4:12pm
pick1998_2 @pick1998_2
@fezziwig2019 So what is the chance for part 2 to be a clear cut success? $ALDX
December 3rd 2019, 4:12pm
pick1998_2 @pick1998_2
@fezziwig2019 I got your point. Nevertheless, isn't the feeling that really bothers dry eyes? $ALDX
December 3rd 2019, 4:12pm
Gambiste1 @Gambiste1
RT @HAG624: @TraderJill77 $ALDX announces positive P3 results for dry eye disease. ?
December 3rd 2019, 4:12pm
Gambiste1 @Gambiste1
RT @Zackfoot: No one should be surprised that Laidlaw reiterated their $30 price target this afternoon after $ALDX PIII interim miss.
December 3rd 2019, 4:12pm
Gambiste1 @Gambiste1
RT @fezziwig2019: @avidresearch Yes let’s exclude 2018 $ALDX Uveitis Endpoint.
December 3rd 2019, 4:12pm
Gambiste1 @Gambiste1
RT @fezziwig2019: @sentivcapital How’d $ALDX Management execute in Anterior Uveitis?
December 3rd 2019, 4:12pm
Gambiste1 @Gambiste1
RT @fezziwig2019: @pick1998_2 “Objective” $ALDX Dry eye staining data says no effect - feelings are so subjective.
December 3rd 2019, 4:12pm
HAG624 @HAG624
@TraderJill77 $ALDX announces positive P3 results for dry eye disease. ?
December 3rd 2019, 3:12pm
StockHorizon @StockHorizon
Intraday DOWN alert max move updates: $ALDX 11% $OTLK 8% https://t.co/cvOhXOn3Pw
December 3rd 2019, 3:12pm
Zackfoot @Zackfoot
No one should be surprised that Laidlaw reiterated their $30 price target this afternoon after $ALDX PIII interim miss.
December 3rd 2019, 2:12pm
fezziwig2019 @fezziwig2019
@avidresearch Yes let’s exclude 2018 $ALDX Uveitis Endpoint.
December 3rd 2019, 2:12pm
fezziwig2019 @fezziwig2019
@sentivcapital How’d $ALDX Management execute in Anterior Uveitis?
December 3rd 2019, 2:12pm
fezziwig2019 @fezziwig2019
@pick1998_2 “Objective” $ALDX Dry eye staining data says no effect - feelings are so subjective.
December 3rd 2019, 2:12pm
Just_Xu_It @Just_Xu_It
Bought $ALDX a little too early ????? but cheap valuation for indications and data. Definitely more positive than n… https://t.co/HuIy2P8h3p
December 3rd 2019, 2:12pm
YuZhu4 @YuZhu4
RT @pick1998_2: $ALDX initiated a small long pos at 5. The data are sort of mixed, but dry eyes is a huge market, and no really effective m…
December 3rd 2019, 2:12pm
pick1998_2 @pick1998_2
$ALDX initiated a small long pos at 5. The data are sort of mixed, but dry eyes is a huge market, and no really eff… https://t.co/k8j0fJgTU3
December 3rd 2019, 2:12pm
YuZhu4 @YuZhu4
RT @pick1998_2: $ALDX dry eye trials are very tough to be robustly positive. Years ago, $EBIO (eleven biotherapeutics) had a fanatic failur…
December 3rd 2019, 1:12pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.